WESTWOOD, Mass. and CAMBRIDGE Mass., Oct. 17 /PRNewswire/ -- The BioSciences Group of Fujitsu Computer Systems today announced a licensing agreement with Ensemble Discovery, a pioneer in synthetic chemistry research, for its BioMedCAChe(TM) suite of automated docking and molecular modeling software. The license will also provide Ensemble with the BioSciences Group's ActiveSite(TM) module for designing effective small molecule inhibitors of protein targets.
"We are glad to provide Ensemble Discovery with the BioMedCAChe automated docking technology," said Dr. Michael J. McManus, Vice President of Business Development for the BioSciences Group. "The goal of the BioSciences Group is to supply innovative companies with powerful modeling tools that can match their workflow challenges and research objectives."
Dr. Arturo J. Morales, Director of Informatics of Ensemble Discovery, said, "At Ensemble, we have a need to conduct sophisticated modeling of both small molecules and nucleic acids in order to better understand and predict the local forces acting on unimolecular reactions. BioMedCAChe brings this capability to the bench scientists directly."
The Fujitsu BioMedCAChe suite provides powerful tools to speed the drug discovery process by enabling scientists to predict and select better quality leads. Analysis capabilities ranging from molecular mechanics to quantum mechanics and ab initio approaches are enabled on small molecules, polymers and macromolecules including proteins and DNA. Scientists can view, analyze and modify structures using interactive sequence and 3D structure editor windows, as well as optimize macromolecules with tens of thousands of atoms, all on their desktop computers.
The BioMedCAChe software also deals with protein-ligand interactions through graphical and analytical models. The ActiveSite option with FastDock(TM) automated docking enables scientists to dock rigid or flexible ligands into a protein with rigid or flexible sidechains. The ActiveSite module is superior to many competing docking packages that are constrained by molecular size and display speed, which require the use of expensive UNIX workstations. BioMedCAChe software is currently the only desktop solution to offer such flexibility in configuration.
About The BioSciences Group of Fujitsu Computer Systems
The BioSciences Group of Fujitsu Computer Systems Corporation is an established leader in creating innovative and reliable solutions for experimental scientists. BioSciences Group solutions enable researchers to make in silico predictions about leads, targets, and interactions, and to validate these hypotheses experimentally. BioSciences Group offerings include the CELLINJECTOR(TM) system for high-throughput, automated cellular injection, the isS(TM) (in silico Screening) platform for large-scale docking and free energy of binding simulations, and the CAChe(TM) suite of life sciences predictive modeling and automated docking tools, for drug discovery lead- generation. For more information, please see: us.fujitsu.com/biosciences.
About Fujitsu Computer Systems
Headquartered in Sunnyvale, Calif., Fujitsu Computer Systems is a wholly owned subsidiary of Fujitsu Limited committed to the design, development and delivery of advanced computer systems and managed services for the business enterprise. The company offers a complete line of high- performance mobile computers, scalable and reliable servers, storage, and middleware as well as managed and professional services. Fujitsu Computer Systems emphasizes leading-edge technology, exceptional product quality and user comfort and productivity, as well as outstanding customer service. More information on Fujitsu Computer Systems is available at: us.fujitsu.com/computers.
Fujitsu is a leading provider of customer-focused IT and communications solutions for the global marketplace. Pace-setting device technologies, highly reliable computing and communications products, and a worldwide corps of systems and services experts uniquely position Fujitsu to deliver comprehensive solutions that open up infinite possibilities for its customers' success. Headquartered in Tokyo, Fujitsu Limited reported consolidated revenues of 4.7 trillion yen (US$44.5 billion) for the fiscal year ended March 31, 2005. For more information, please see: www.fujitsu.com.
About Ensemble Discovery Corporation
Located in Cambridge, MA, Ensemble Discovery Corporation is an early stage company that is transforming the way scientists discover novel chemicals. Based on the groundbreaking work of Professor David Liu of Harvard University, DNA Programmed Chemistry (DPC(TM)) utilizes a specially designed genetic code to control chemical reactivity and guide the assembly of chemical structures. Ensemble has integrated DPC(TM) into a unique selection system that combines chemistry, biology and informatics to discover novel compounds. Ensemble utilizes DPC(TM) to generate new products that address significant unmet needs in therapeutics, detection and other specialty chemical markets.
NOTE: Fujitsu, BioMedCAChe, ActiveSite, CELLINJECTOR, isS, FastDock and CAChe are trademarks or registered trademarks of Fujitsu Limited in the United States and other countries. DPC is a trademark of Ensemble Discovery Corporation in the United States and other countries. All other trademarks and product names are the property of their respective owners.
BioSciences Group of Fujitsu Computer Systems